Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01158222 · ClinicalTrials.gov registry record · Phase 2
Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT01158222 is a Phase 2 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 37 participants.
The verdict
NCT01158222, a Phase 2 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib malate it works in treating patients with previously untreated metastatic kidney cancer.
Interventions
- DRUG sunitinib malate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2010-08-18 |
| Est. Completion | 2017-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01158222
The ClinicalTrials.gov registry entry for NCT01158222 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sunitinib malate is the first listed.
NCT01158222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01158222 about?
NCT01158222 is a clinical study titled "Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer". RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib malate it works in treating patients with previously untreated metastatic kidney ...
What is the current status of trial NCT01158222?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2010-08-18. Estimated completion is 2017-02-01.
What interventions are being tested in trial NCT01158222?
The interventions under investigation include: sunitinib malate (DRUG).
Who is sponsoring clinical trial NCT01158222?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.